Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of TAS-114 plus S-1 versus S-1 in advanced or metastatic non-small cell lung cancer
2016-001806-40Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing TAS-114 + S-1 with S-1 monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2016; status: completed.
02
Drugs
TAS-114tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001806-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001806-40.